In this episode of Conversations in Drug Development, Boyds’ regulatory experts Eric Hardter and Kelsey Lenoch explore the latest shifts within the US FDA landscape and what they mean for drug developers navigating an increasingly dynamic regulatory environment.
From leadership changes and evolving review priorities to new initiatives aimed at improving transparency, efficiency, and innovation — the FDA landscape continues to transform.
Tune in for a timely and insightful discussion offering expert perspectives on how these developments could shape the next phase of drug development.
Listen now by searching “Conversations in Drug Development” on Spotify, Amazon or Apple Podcasts.